R&D Model Needs ‘Radical Reshaping,’ Says UK Report
Executive Summary
A new report has identified a number of ways to boost the productivity of drug research and development at small and medium-sized companies, including new R&D tools and models, more collaborative approaches and better use of the huge amounts of data being generated.
You may also be interested in...
Will ‘Transformative’ UK Life Sciences Sector Deal Help Offset The Brexit Effect?
The UK government has published its life sciences sector deal, which it says will allow the UK to respond to the challenges and opportunities of demographic change and pioneering research and development – although there is no mention of the “Brexit effect.”
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.